In re Bystolic Antitrust Litigation
Case Number:
23-410
Court:
Nature of Suit:
Companies
- AbbVie Inc.
- Albertsons Cos. Inc.
- Alkem Laboratories Ltd.
- Allergan PLC
- Amerigen Pharmaceuticals Ltd.
- Ascend Laboratories LLC
- Association for Accessible Medicines
- CVS Health Corp.
- Forest Laboratories Inc.
- Glenmark Pharmaceuticals Ltd.
- Hetero Drugs Ltd.
- J.M. Smith Corp.
- New Civil Liberties Alliance
- Rite Aid Corp.
- Teva Pharmaceutical Industries Ltd.
- The Kroger Co.
- Torrent Pharmaceuticals Ltd.
- United Food & Commercial Workers International Union
- Washington Legal Foundation
Government Agencies
Sectors & Industries:
-
May 13, 2024
2nd Circ. Affirms Dismissal Of Bystolic Antitrust Suit
The Second Circuit issued its first decision under the high court's Actavis "pay for delay" ruling on Monday, affirming the dismissal of a case alleging that an AbbVie predecessor delayed competition for its hypertension treatment Bystolic through deals with several generic makers.
-
December 06, 2023
Patent Suit Deal Sounds Like 'Money Laundering' To Judge
One of the alleged reverse payments at the heart of a pharmaceutical antitrust case "sounds a little bit like money laundering," a Second Circuit judge said Wednesday as an appellate panel was asked to nail down the pleading standard for a lawsuit related to the hypertension drug Bystolic.
-
July 21, 2023
AbbVie Gets Amicus Backing In 2nd Circ. Bystolic Suit
A free market legal think tank on Friday blasted the Federal Trade Commission as a "lawless agency" with no credibility, in an amicus brief urging the Second Circuit to ignore the FTC's position in an antitrust case involving the hypertension drug Bystolic.
-
June 21, 2023
FTC Urges 2nd Circ. To Revive Bystolic Antitrust Case
The Federal Trade Commission urged the Second Circuit to revive claims from Bystolic buyers alleging that an AbbVie predecessor struck deals with several generic makers to delay competition for its hypertension treatment, saying the deals may violate antitrust law.